Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of EGb 761 120 mg twice daily versus placebo in patients with Friedreich ataxia
2007-005371-34Phase 2Completed
- Sponsor
- Ipsen
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Friedreich ataxia (FA) comparing EGb 761 120 mg twice daily with Placebo (2 arms). Primary endpoint: Creatine rephosphorylation rate post-exercise. Started Dec 2007; status: completed.
02
Drugs
ginkgo biloba extract
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on 2007-005371-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005371-34.